JP2018512157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512157A5 JP2018512157A5 JP2017553885A JP2017553885A JP2018512157A5 JP 2018512157 A5 JP2018512157 A5 JP 2018512157A5 JP 2017553885 A JP2017553885 A JP 2017553885A JP 2017553885 A JP2017553885 A JP 2017553885A JP 2018512157 A5 JP2018512157 A5 JP 2018512157A5
- Authority
- JP
- Japan
- Prior art keywords
- binding agent
- isolated
- acid sequence
- chain polypeptide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011230 binding agent Substances 0.000 claims 20
- 229920001184 polypeptide Polymers 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 206010037575 Pustular psoriasis Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 5
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 5
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 5
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 201000010914 pustulosis of palm and sole Diseases 0.000 claims 4
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 108091007973 Interleukin-36 Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000003786 sclera Anatomy 0.000 claims 2
- 101000852965 Homo sapiens Interleukin-1 receptor-like 2 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000048133 human IL1RL2 Human genes 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021069306A JP7212098B2 (ja) | 2015-04-15 | 2021-04-15 | インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体 |
| JP2023003385A JP7721585B2 (ja) | 2015-04-15 | 2023-01-12 | インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体 |
| JP2025127775A JP2025163120A (ja) | 2015-04-15 | 2025-07-30 | インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562147824P | 2015-04-15 | 2015-04-15 | |
| US62/147,824 | 2015-04-15 | ||
| PCT/US2016/027676 WO2016168542A1 (en) | 2015-04-15 | 2016-04-15 | Antibodies directed against interleukin 36 receptor (il-36r) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021069306A Division JP7212098B2 (ja) | 2015-04-15 | 2021-04-15 | インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512157A JP2018512157A (ja) | 2018-05-17 |
| JP2018512157A5 true JP2018512157A5 (enExample) | 2019-05-23 |
| JP6913026B2 JP6913026B2 (ja) | 2021-08-04 |
Family
ID=57126337
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553885A Active JP6913026B2 (ja) | 2015-04-15 | 2016-04-15 | インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体 |
| JP2021069306A Active JP7212098B2 (ja) | 2015-04-15 | 2021-04-15 | インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体 |
| JP2023003385A Active JP7721585B2 (ja) | 2015-04-15 | 2023-01-12 | インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体 |
| JP2025127775A Pending JP2025163120A (ja) | 2015-04-15 | 2025-07-30 | インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021069306A Active JP7212098B2 (ja) | 2015-04-15 | 2021-04-15 | インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体 |
| JP2023003385A Active JP7721585B2 (ja) | 2015-04-15 | 2023-01-12 | インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体 |
| JP2025127775A Pending JP2025163120A (ja) | 2015-04-15 | 2025-07-30 | インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10526410B2 (enExample) |
| EP (2) | EP4176900A1 (enExample) |
| JP (4) | JP6913026B2 (enExample) |
| KR (1) | KR102666920B1 (enExample) |
| CN (2) | CN107847590B (enExample) |
| AU (1) | AU2016248208B2 (enExample) |
| CA (1) | CA2982555A1 (enExample) |
| DK (1) | DK3283110T3 (enExample) |
| ES (1) | ES2914243T3 (enExample) |
| MX (2) | MX2017013080A (enExample) |
| PL (1) | PL3283110T3 (enExample) |
| RU (1) | RU2745898C2 (enExample) |
| SG (1) | SG11201708061TA (enExample) |
| WO (1) | WO2016168542A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS67639B1 (sr) | 2011-11-16 | 2026-02-27 | Boehringer Ingelheim Int | Anti il-36r antitela |
| RU2745898C2 (ru) * | 2015-04-15 | 2021-04-02 | Анаптисбайо, Инк. | Антитела, направленные против рецептора интерлейкина 36 (il-36r) |
| US20180273627A1 (en) * | 2017-03-27 | 2018-09-27 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies combination therapy |
| EP3400962A1 (en) * | 2017-05-09 | 2018-11-14 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | Inhibitors of il-38 for use in treating and/or preventing cancer in a subject |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| AU2019236105B2 (en) * | 2018-03-14 | 2025-07-31 | Boehringer Ingelheim International Gmbh | Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis |
| WO2019177883A2 (en) * | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease |
| IL280013B2 (en) | 2018-07-16 | 2026-05-01 | Regeneron Pharmaceuticals Inc | Anti-IL36R antibodies |
| IL315703A (en) | 2018-07-16 | 2024-11-01 | Regeneron Pharma | Non-human animal models of DITRA disease and their uses |
| CN110818796B (zh) * | 2018-08-09 | 2022-11-08 | 东莞市朋志生物科技有限公司 | 一种抗人ca153蛋白的重组抗体 |
| US11884719B2 (en) * | 2018-12-21 | 2024-01-30 | 23Andme, Inc. | Anti-IL-36 antibodies and methods of use thereof |
| TW202037604A (zh) * | 2018-12-27 | 2020-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 治療掌蹠膿疱症之抗il-36r抗體 |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| EA202192405A1 (ru) | 2019-03-08 | 2022-01-13 | Бёрингер Ингельхайм Интернациональ Гмбх | Составы антител против il-36r |
| JP7802651B2 (ja) | 2019-08-07 | 2026-01-20 | アクアラン セラピューティクス コーポレーション | 抗ｎａｍｐｔ抗体及びその用途 |
| JP7811772B2 (ja) * | 2019-12-05 | 2026-02-06 | 学校法人東京薬科大学 | 筋組織の減少を抑制するための組成物 |
| AR120913A1 (es) * | 2019-12-27 | 2022-03-30 | Teijin Pharma Ltd | Anticuerpo que inhibe específicamente la señalización de il-36r |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| EP4182022A1 (en) | 2020-07-17 | 2023-05-24 | Boehringer Ingelheim International GmbH | Anti-il-36r antibodies for the treatment of neutrophilic dermatoses |
| JP2023536851A (ja) * | 2020-07-30 | 2023-08-30 | アナプティスバイオ インコーポレイティッド | 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法 |
| WO2022026829A1 (en) | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity |
| CN112094349B (zh) * | 2020-11-04 | 2021-02-09 | 上海华奥泰生物药业股份有限公司 | 靶向于白介素36r的抗体及其制备方法和应用 |
| WO2022150642A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa |
| WO2022150644A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for acne |
| MX2023010289A (es) * | 2021-03-04 | 2023-09-11 | Boehringer Ingelheim Int | Uso de anticuerpos anti-il-36r en el tratamiento de la psoriasis pustulosa generalizada. |
| EP4305207A2 (en) | 2021-03-12 | 2024-01-17 | Boehringer Ingelheim International GmbH | Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis |
| AU2022274319A1 (en) * | 2021-05-12 | 2024-01-04 | Anaptysbio, Inc. | Antibody composition |
| EP4370550A1 (en) | 2021-07-12 | 2024-05-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of il-36 inhibitors for the treatment of netherton syndrome |
| TW202323293A (zh) * | 2021-10-29 | 2023-06-16 | 新加坡商創響私人有限公司 | 新型抗ｉｌ－３６ｒ抗體 |
| CN115724975A (zh) * | 2022-10-20 | 2023-03-03 | 江苏荃信生物医药股份有限公司 | 抗人白介素36受体单克隆抗体及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| WO1992008796A1 (en) | 1990-11-13 | 1992-05-29 | Immunex Corporation | Bifunctional selectable fusion genes |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| WO2001057219A2 (en) | 2000-02-02 | 2001-08-09 | Schering Corporation | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| DE60226641D1 (de) | 2001-12-03 | 2008-06-26 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| CA2662549C (en) | 2006-09-08 | 2014-10-28 | Amgen Inc. | Il-1 family variants |
| NZ579010A (en) | 2007-02-20 | 2012-03-30 | Anaptysbio Inc | Somatic hypermutation systems |
| KR20110048536A (ko) | 2008-08-28 | 2011-05-11 | 와이어쓰 엘엘씨 | 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도 |
| US20140234330A1 (en) * | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| RS67639B1 (sr) * | 2011-11-16 | 2026-02-27 | Boehringer Ingelheim Int | Anti il-36r antitela |
| EP2797952B1 (en) * | 2011-12-28 | 2019-02-27 | ImmunoQure AG | Method of providing monoclonal auto-antibodies with desired specificity |
| US9409977B2 (en) | 2013-03-12 | 2016-08-09 | Decimmune Therapeutics, Inc. | Humanized, anti-N2 antibodies |
| RU2745898C2 (ru) * | 2015-04-15 | 2021-04-02 | Анаптисбайо, Инк. | Антитела, направленные против рецептора интерлейкина 36 (il-36r) |
| US20180273627A1 (en) | 2017-03-27 | 2018-09-27 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies combination therapy |
| AU2019236105B2 (en) | 2018-03-14 | 2025-07-31 | Boehringer Ingelheim International Gmbh | Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis |
| WO2019177883A2 (en) | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease |
| IL280013B2 (en) | 2018-07-16 | 2026-05-01 | Regeneron Pharmaceuticals Inc | Anti-IL36R antibodies |
| US11884719B2 (en) | 2018-12-21 | 2024-01-30 | 23Andme, Inc. | Anti-IL-36 antibodies and methods of use thereof |
| TW202037604A (zh) | 2018-12-27 | 2020-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 治療掌蹠膿疱症之抗il-36r抗體 |
| EA202192405A1 (ru) | 2019-03-08 | 2022-01-13 | Бёрингер Ингельхайм Интернациональ Гмбх | Составы антител против il-36r |
| US20220233710A1 (en) | 2019-05-20 | 2022-07-28 | Nantong Yichen Biopharma. Co. Ltd. | Bispecific molecule and preparation and use thereof |
-
2016
- 2016-04-15 RU RU2017139481A patent/RU2745898C2/ru active
- 2016-04-15 EP EP22162381.2A patent/EP4176900A1/en active Pending
- 2016-04-15 CA CA2982555A patent/CA2982555A1/en active Pending
- 2016-04-15 CN CN201680034793.6A patent/CN107847590B/zh active Active
- 2016-04-15 PL PL16780800T patent/PL3283110T3/pl unknown
- 2016-04-15 KR KR1020177032985A patent/KR102666920B1/ko active Active
- 2016-04-15 CN CN202210803364.8A patent/CN115925932A/zh active Pending
- 2016-04-15 MX MX2017013080A patent/MX2017013080A/es unknown
- 2016-04-15 ES ES16780800T patent/ES2914243T3/es active Active
- 2016-04-15 SG SG11201708061TA patent/SG11201708061TA/en unknown
- 2016-04-15 DK DK16780800.5T patent/DK3283110T3/da active
- 2016-04-15 AU AU2016248208A patent/AU2016248208B2/en active Active
- 2016-04-15 EP EP16780800.5A patent/EP3283110B1/en active Active
- 2016-04-15 JP JP2017553885A patent/JP6913026B2/ja active Active
- 2016-04-15 WO PCT/US2016/027676 patent/WO2016168542A1/en not_active Ceased
- 2016-04-15 US US15/567,045 patent/US10526410B2/en active Active
-
2017
- 2017-10-11 MX MX2023001791A patent/MX2023001791A/es unknown
-
2019
- 2019-11-18 US US16/686,373 patent/US11130814B2/en active Active
-
2021
- 2021-04-15 JP JP2021069306A patent/JP7212098B2/ja active Active
- 2021-08-26 US US17/412,737 patent/US12391761B2/en active Active
-
2023
- 2023-01-12 JP JP2023003385A patent/JP7721585B2/ja active Active
-
2025
- 2025-07-24 US US19/279,706 patent/US20260022181A1/en active Pending
- 2025-07-30 JP JP2025127775A patent/JP2025163120A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539245A5 (enExample) | ||
| HRP20130228T1 (hr) | Antitijela s visokim afinitetom za receptor humanog il 6 | |
| JP2009521909A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| JP2017523786A5 (enExample) | ||
| JP2017530722A5 (enExample) | ||
| JP2021535733A (ja) | Ｉｌ−１１抗体 | |
| RU2017137872A (ru) | Композиции для ингибирования masp-2-зависимой активации комплемента | |
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2012525829A5 (enExample) | ||
| JP2017113028A5 (enExample) | ||
| JP2015530971A5 (enExample) | ||
| SI2593128T1 (en) | Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures | |
| JP2010526028A5 (enExample) | ||
| HRP20201375T1 (hr) | ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE | |
| JP2009540018A5 (enExample) | ||
| TW201323441A (zh) | 抗ｔｎｆ之雙特異性免疫結合物 | |
| JP2011509245A5 (enExample) | ||
| TW201233795A (en) | Chemokine receptor binding polypeptides | |
| WO2009052081A4 (en) | Antibodies that bind il-4 and/or il-13 and their uses | |
| JP2014500009A5 (enExample) | ||
| JP2011256213A5 (enExample) | ||
| JP2010507594A5 (enExample) | ||
| JP2017522903A5 (enExample) | ||
| JP2018093875A5 (enExample) |